Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Ambra Di Tommaso"'
Autor:
Mauro Di Ianni, Beatrice Del Papa, Stefano Baldoni, Ambra Di Tommaso, Bianca Fabi, Emanuela Rosati, Annalisa Natale, Stella Santarone, Paola Olioso, Gabriele Papalinetti, Raffaella Giancola, Patrizia Accorsi, Paolo Di Bartolomeo, Paolo Sportoletti, Franca Falzetti
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
In allogeneic hematopoietic stem cell transplantation, which is the major curative therapy for hematological malignancies, T cells play a key role in the development of graft-versus-host disease (GvHD). NOTCH pathway is a conserved signal transductio
Externí odkaz:
https://doaj.org/article/8f236388b87f4c4591b90c05041343c9
Autor:
Mauro Di Ianni, Stefano Baldoni, Beatrice Del Papa, Patrizia Aureli, Erica Dorillo, Filomena De Falco, Elisa Albi, Emanuela Varasano, Ambra Di Tommaso, Raffaella Giancola, Patrizia Accorsi, Gianluca Rotta, Chiara Rompietti, Estevão Carlos Silva Barcelos, Antonio Francesco Campese, Paolo Di Bartolomeo, Isabella Screpanti, Emanuela Rosati, Franca Falzetti, Paolo Sportoletti
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
To investigate chronic lymphocytic leukemia (CLL)-initiating cells, we assessed NOTCH1 mutation/expression in hematopoietic stem cells (HSCs). In NOTCH1-mutated CLL, we detected subclonal mutations in 57% CD34+/CD38− HSCs. NOTCH1 mutation was prese
Externí odkaz:
https://doaj.org/article/22cb5b5b90a04145889dadc04b8f6e35
Autor:
Stefano Guadagni, Giammaria Fiorentini, Marco Clementi, Giancarlo Palumbo, Paola Palumbo, Alessandro Chiominto, Stefano Baldoni, Francesco Masedu, Marco Valenti, Ambra Di Tommaso, Bianca Fabi, Camillo Aliberti, Donatella Sarti, Veronica Guadagni, Cristina Pellegrini
Publikováno v:
International Journal of Molecular Sciences, Vol 18, Iss 11, p 2382 (2017)
Pelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25% of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic perfusion may, therefore, be an option for these non-responsive pati
Externí odkaz:
https://doaj.org/article/ef5bf75e5a8b44078dbd67b4b00cc821
Autor:
Daria Capece, Francesca Zazzeroni, Maria Michela Mancarelli, Daniela Verzella, Mariafausta Fischietti, Ambra Di Tommaso, Rita Maccarone, Sara Plebani, Mauro Di Ianni, Alberto Gulino, Edoardo Alesse
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e68080 (2013)
The Ikaros gene encodes a Krüppel-like zinc-finger transcription factor involved in hematopoiesis regulation. Ikaros has been established as one of the most clinically relevant tumor suppressors in several hematological malignancies. In fact, expres
Externí odkaz:
https://doaj.org/article/8fabe299cda847c39a478c7ed7db71a0
Autor:
Paolo Sportoletti, Emanuela Rosati, Mauro Di Ianni, Franca Falzetti, Maria Paola Martelli, Guido Montanaro, Andrea Marra, Ambra Di Tommaso, Roberta Iacucci Ostini, Elisa Albi, Estevão Carlos Silva Barcelos, Federica Mezzasoma, Francesco Maria Adamo, Manuel Nogarotto, Daniele Sorcini, Maria Grazia Cantelmi, Debora Cecchini, Chiara Rompietti, Filomena De Falco, Erica Dorillo, Stefano Baldoni, Beatrice Del Papa
Figure S4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bec17ba17c9787a614b9bbd2801f41c
https://doi.org/10.1158/1078-0432.22471380
https://doi.org/10.1158/1078-0432.22471380
Autor:
Paolo Sportoletti, Emanuela Rosati, Mauro Di Ianni, Franca Falzetti, Maria Paola Martelli, Guido Montanaro, Andrea Marra, Ambra Di Tommaso, Roberta Iacucci Ostini, Elisa Albi, Estevão Carlos Silva Barcelos, Federica Mezzasoma, Francesco Maria Adamo, Manuel Nogarotto, Daniele Sorcini, Maria Grazia Cantelmi, Debora Cecchini, Chiara Rompietti, Filomena De Falco, Erica Dorillo, Stefano Baldoni, Beatrice Del Papa
Supplementary Figure Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08213d6c0f6644f20568831b0e789e00
https://doi.org/10.1158/1078-0432.22471362.v1
https://doi.org/10.1158/1078-0432.22471362.v1
Autor:
Paolo Sportoletti, Emanuela Rosati, Mauro Di Ianni, Franca Falzetti, Maria Paola Martelli, Guido Montanaro, Andrea Marra, Ambra Di Tommaso, Roberta Iacucci Ostini, Elisa Albi, Estevão Carlos Silva Barcelos, Federica Mezzasoma, Francesco Maria Adamo, Manuel Nogarotto, Daniele Sorcini, Maria Grazia Cantelmi, Debora Cecchini, Chiara Rompietti, Filomena De Falco, Erica Dorillo, Stefano Baldoni, Beatrice Del Papa
Purpose:Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), has improved the outcomes of chronic lymphocytic leukemia (CLL), but primary resistance or relapse are issues of increasing significance. While the predominant mechanism of action of BTKi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32ff165291a87757c7b419c2e16d63a2
https://doi.org/10.1158/1078-0432.c.6527862
https://doi.org/10.1158/1078-0432.c.6527862
Autor:
Paolo Sportoletti, Emanuela Rosati, Mauro Di Ianni, Franca Falzetti, Maria Paola Martelli, Guido Montanaro, Andrea Marra, Ambra Di Tommaso, Roberta Iacucci Ostini, Elisa Albi, Estevão Carlos Silva Barcelos, Federica Mezzasoma, Francesco Maria Adamo, Manuel Nogarotto, Daniele Sorcini, Maria Grazia Cantelmi, Debora Cecchini, Chiara Rompietti, Filomena De Falco, Erica Dorillo, Stefano Baldoni, Beatrice Del Papa
Tables S1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b72ae2fb7c88075d972832722c2a1c
https://doi.org/10.1158/1078-0432.22471359.v1
https://doi.org/10.1158/1078-0432.22471359.v1
Autor:
Daniele Sorcini, Manuel Nogarotto, Beatrice Del Papa, Paolo Sportoletti, Erica Dorillo, Mauro Di Ianni, Emanuela Rosati, Francesco Maria Adamo, Filomena De Falco, Maria Paola Martelli, Stefano Baldoni, Elisa Albi, Federica Mezzasoma, Roberta Iacucci Ostini, Chiara Rompietti, Franca Falzetti, Andrea Marra, Maria Grazia Cantelmi, Ambra Di Tommaso, Debora Cecchini, Estevão Carlos Silva Barcelos, Guido Montanaro
Publikováno v:
Clinical Cancer Research. 25:7540-7553
Purpose: Ibrutinib, a Bruton tyrosine kinase inhibitor (BTKi), has improved the outcomes of chronic lymphocytic leukemia (CLL), but primary resistance or relapse are issues of increasing significance. While the predominant mechanism of action of BTKi
Autor:
Francesco Masedu, Cristina Pellegrini, Giammaria Fiorentini, Stefano Baldoni, Stefano Guadagni, Bianca Fabi, Veronica Guadagni, Giancarlo Palumbo, Marco Clementi, Marco Valenti, Paola Palumbo, Ambra Di Tommaso, Camillo Aliberti, Alessandro Chiominto, Donatella Sarti
Publikováno v:
International Journal of Molecular Sciences, Vol 18, Iss 11, p 2382 (2017)
International Journal of Molecular Sciences; Volume 18; Issue 11; Pages: 2382
International Journal of Molecular Sciences
International Journal of Molecular Sciences; Volume 18; Issue 11; Pages: 2382
International Journal of Molecular Sciences
Pelvic Melanoma relapse occurs in 15% of patients with loco regional metastases, and 25% of cases do not respond to new target-therapy and/or immunotherapy. Melphalan hypoxic pelvic perfusion may, therefore, be an option for these non-responsive pati